Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Rubinstein, Jeremy D  [Clear All Filters]
Journal Article
Afify Z, Orjuela-Grimm M, Smith CMoore, Dalal M, Ford JB, Pillai P, Robles JM, Reddy S, McCormack S, Ehrhardt MJ, et al. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative. Br J Haematol. 2022.
Gross TG, Rubinstein JD. Post-transplant lymphoproliferative disease in children, adolescents, and young adults. Hematol Oncol. 2023;41 Suppl 1:48-56.
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray LM, Thomas S, Dourson C, Wilhelm J, Lane A, et al. Scheduled Administration of Virus-Specific T cells for Viral Prophylaxis After Pediatric Allogeneic Stem Cell Transplant. Blood Adv. 2022.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YZM, Hanley PJ, Keller MD, Bollard CM, et al. Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther. 2023.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang YZ, Heyenbruch D, Bollard CM, Keller MD, et al. Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am J Transplant. 2024.
Green A, Rubinstein JD, Grimley M, Pfeiffer T. Virus-Specific T Cells for the Treatment of Systemic Infections Following Allogeneic Hematopoietic Cell and Solid Organ Transplantation. J Pediatric Infect Dis Soc. 2024;13(Supplement_1):S49-S57.